Amgen's $37B Biological Arsenal: Navigating Patent Cliffs While Betting Big on Obesity and AI-Designed Proteins

Amgen closed FY2025 with $36.8B in revenue (+10% YoY) and 14 billion-dollar products, but faces simultaneous patent cliffs on Prolia and XGEVA while racing MariTide through six Phase 3 obesity trials. Today, tarlatamab won China approval, expanding the company's bispecific T-cell engager franchise into the world's largest lung cancer market.

AMGN · Health Care · April 10, 2026

S&P 500 Position

Amgen is the largest pure-play biotech in the S&P 500 by revenue and sits among the top 5 healthcare companies in the index alongside UnitedHealth Group, Eli Lilly, Johnson & Johnson, and AbbVie. It competes directly with AbbVie in inflammation, Lilly and Novo Nordisk in obesity, Merck/Roche in oncology, and an emerging wave of biosimilar-focused companies. Its Dow Jones Industrial Average membership (one of only 30 components) gives it outsized visibility relative to its index weight. As a DJIA member, it is price-weighted — and at ~$351/share, it has meaningful impact on that index.

Index Weight: ~0.42% | Rank: Approximately #40-50 in S&P 500 by market cap

Company Overview

Amgen is executing one of the most complex portfolio transitions in biotech history. On one side, its legacy denosumab franchise (Prolia and XGEVA, combined ~$6B+ in 2025 sales) faces accelerated biosimilar erosion starting this year, and Enbrel's revenue collapsed 33% in FY2025 under Medicare Part D pricing pressure. On the other side, the company is aggressively scaling newer growth engines: Repatha (up 36% to $3B annualized), TEZSPIRE (up 52% to $1.5B), IMDELLTRA/tarlatamab ($627M in its first full year), and EVENITY (up 34% to $2.1B). Fourteen products now exceed $1 billion in annual sales, a diversification depth unmatched in large-cap biotech. The strategic center of gravity is MariTide (maridebart cafraglutide), Amgen's antibody-peptide conjugate for obesity. As a GLP-1 agonist / GIPR antagonist with monthly-or-less-frequent dosing, MariTide occupies a differentiated position in the obesity landscape dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound — both requiring weekly injections. Phase 2 data showed up to ~20% weight loss at 52 weeks without plateau, though the full dataset revealed GI tolerability challenges and high discontinuation in fixed-dose arms, leading Amgen to redesign Phase 3 dosing with a three-step escalation. Six global Phase 3 MARITIME studies are underway across chronic weight management, cardiovascular outcomes, heart failure, and obstructive sleep apnea — with the two weight management studies fully enrolled. Amgen simultaneously operates one of pharma's most aggressive bispecific T-cell engager (BiTE) programs. Tarlatamab (IMDELLTRA) received FDA traditional approval in November 2025 after demonstrating a 40% reduction in death risk versus standard chemotherapy in second-line small cell lung cancer. The DLL3-targeting bispecific just won China approval today via partner BeOne Medicines, and combination trials (DeLLphi-303 frontline, DeLLphi-306 limited-stage) are expanding its addressable market. Xaluritamig, a STEAP1 x CD3 bispecific for metastatic castration-resistant prostate cancer, is in two Phase 3 studies. Olpasiran, an siRNA targeting Lp(a), is pursuing cardiovascular outcomes in the OCEAN(a) program and could open an entirely new therapeutic category if it demonstrates MACE reduction.

Products & Revenue

Amgen operates as a single reportable segment (human therapeutics) but organizes commercially across four therapeutic areas: General Medicine (~$11B FY2025), Oncology (~$10B), Inflammation (~$7B), and Rare Disease (~$5B). Revenue is heavily driven by volume growth (13% in FY2025) offsetting 3% net price declines. The portfolio is notably broad: 14 products exceeded $1 billion in annual sales in 2025, and 18 products hit record sales. Biosimilars contributed approximately $3 billion in 2025, up 37% YoY.

General Medicine (Repatha, Prolia, EVENITY, Aranesp) (~31%): Anchored by Repatha (PCSK9 inhibitor for cardiovascular disease, $3B+ annualized after broadened FDA label), Prolia (denosumab for osteoporosis, facing biosimilar erosion), and EVENITY (romosozumab for osteoporosis, $2.1B and growing 34%).

Oncology (BLINCYTO, XGEVA, Kyprolis, Vectibix, IMDELLTRA, Nplate) (~28%): BiTE platform drives growth via BLINCYTO (blinatumomab for B-ALL) and IMDELLTRA (tarlatamab for SCLC, $627M first full year). XGEVA faces biosimilar erosion; Kyprolis and Vectibix are steady oncology workhorses.

Inflammation (Enbrel, Otezla, TEZSPIRE, AMJEVITA/AMGEVITA) (~20%): TEZSPIRE (tezepelumab for severe asthma, up 52% to $1.5B) is the growth engine as Enbrel ($2.2B, down 33%) and Otezla ($1.2B, IRA-impacted) decline. AMJEVITA (Humira biosimilar) adds incremental contribution.

Rare Disease (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS) (~14%): Acquired via Horizon Therapeutics (2023). TEPEZZA (teprotumumab for thyroid eye disease) and KRYSTEXXA (pegloticase for chronic gout) anchor the franchise. UPLIZNA grew 73% in 2025 with new IgG4-RD and gMG approvals.

Biosimilars Portfolio (MVASI, AMJEVITA, Pavblu, Wezlana, others) (~8%): ~$3B in FY2025 sales across biosimilars for Avastin, Humira, Eylea, Soliris, and others. Phase 3 biosimilars for Opdivo, Keytruda, and Ocrevus represent the next wave of launches.

Based on FY2025 10-K filing (period ending Dec 31, 2025, filed Feb 2026) and Q4 2025 earnings release. Amgen reports as a single operating segment; therapeutic area breakdowns are based on product-level disclosures.

Leadership

Robert A. Bradway

CEO since 2012. Bradway holds a B.S. in biology from Amherst College and an MBA from Harvard. Before joining Amgen in 2006, he spent nearly two decades as a healthcare investment banker at Morgan Stanley, including as Managing Director and Head of International Banking in London. He has led Amgen's transformation from an ESA/Neulasta-dependent company into a diversified $37B biotech, overseeing the $28B Horizon Therapeutics acquisition and the company's pivot into obesity and AI-driven drug discovery.

Jay Bradner, M.D., Executive Vice President, Research and Development & Chief Scientific Officer: Joined Amgen in late 2023 from the presidency of the Novartis Institutes for BioMedical Research (NIBR). Previously an associate professor at Harvard Medical School and clinician at Dana-Farber Cancer Institute. Leading Amgen's entire R&D portfolio including the MariTide obesity program and BiTE oncology platform.

David M. Reese, M.D., Executive Vice President & Chief Technology Officer: Amgen's inaugural CTO, transitioned from leading R&D over an 18-year tenure. Oversees the integration of AI, automation, and generative biology across R&D, manufacturing, and commercial operations. Architect of Amgen's NVIDIA partnership and the Freyja supercomputer deployment at deCODE genetics.

Peter H. Griffith, Executive Vice President & Chief Financial Officer: CFO since 2020, previously Global Vice Chairman of Corporate Development at EY and Managing Director at Wedbush Securities. Orchestrating Amgen's deleveraging strategy — $6B in debt retired in 2025 — while guiding 2026 revenue guidance of $37.0-$38.4B.

Sean Bruich, Senior Vice President, Artificial Intelligence and Data: Leads Amgen's enterprise AI strategy, including the OpenAI partnership and rollout of ChatGPT Enterprise across the company. Responsible for translating AI capabilities into drug discovery workflows, clinical trial optimization, and commercial operations.

Kári Stefánsson, Founder & CEO, deCODE Genetics (Amgen subsidiary): Oversees one of the world's largest human genomic datasets — 200+ petabytes of de-identified data from nearly 3 million individuals. deCODE's population-scale genetics capability provides Amgen's foundational advantage in genetically validated target selection.

The AI Angle

Designing proteins with AI, not discovering them

Amgen has built one of the most vertically integrated AI-for-drug-discovery operations in pharma. The company's AMPLIFY protein language model, co-developed with Mila (the Quebec AI institute), teaches AI the 'language' of proteins to enable de novo protein design rather than traditional screening. Amgen scientists trained five antibody-specific large language models using NVIDIA BioNeMo on DGX Cloud, fine-tuning the ESM-1nv protein LLM with proprietary antibody data. This generative biology platform — operating in a continuous 'design → make → test → learn' loop — has tripled protein engineering speed and cut discovery timelines in half, according to the company. The platform shift is fundamental: Amgen is moving from screening millions of candidate molecules to computationally designing proteins with desired therapeutic properties from the outset. The infrastructure commitment is serious. Amgen deployed an NVIDIA DGX SuperPOD — named 'Freyja' — at its deCODE genetics subsidiary's headquarters in Reykjavik, Iceland. The system features 31 DGX H100 nodes with 248 H100 Tensor Core GPUs, purpose-built to train AI models against deCODE's 200+ petabyte dataset of de-identified human genomic, transcriptomic, and proteomic data from nearly 3 million individuals. The goal is building a human diversity atlas for drug target and biomarker discovery, and developing AI-driven precision medicine models. David Reese, Amgen's CTO, has framed this as a 'hinge moment' where the union of technology and biotechnology fundamentally reshapes the industry. Amgen was also an early adopter of OpenAI's ChatGPT Enterprise, rolling it out across the company in a phased manner with enterprise security integration. On the talent side, the AI operation sits at the intersection of several leaders. CTO David Reese (a physician-scientist turned technology executive) provides strategic direction. Sean Bruich (SVP, AI and Data) leads the enterprise AI rollout. Chris James Langmead (Director of Digital Biologics Discovery) runs the BioNeMo-powered protein engineering work. Marti Head (Executive Director, Computational and Data Sciences) leads the modeling teams. The company also explores federated learning to train models across organizations without sharing raw data, acknowledging that no single company's protein dataset captures enough biological diversity. Competitively, Amgen's AI position is differentiated by the deCODE genetics moat — few pharma companies have access to population-scale genomic data at this depth. Sanofi has partnered with Formation Bio and OpenAI, Lilly is building in-house capabilities, and Recursion and Insilico Medicine are pure-play AI drug discovery companies. Amgen's advantage is the closed loop between AI-based target identification (deCODE data), AI-assisted protein design (AMPLIFY/BioNeMo), and one of the world's largest biologics manufacturing networks. The risk is execution: AI-designed molecules still need to survive the same clinical trial gauntlet, and none of Amgen's commercially launched products to date were AI-discovered.

Financial Snapshot

Revenue (TTM): $36.8B — FY2025 | Net Income: $7.7B net income (GAAP)

Margins: GAAP operating margin 25.8%, non-GAAP operating margin ~48.9% (Q2 2025 peak), net margin 21.0%

Amgen's financial profile is defined by the tension between strong operating performance and heavy debt. FY2025 non-GAAP EPS grew 10% to $21.84, and the company generated $8.1B in free cash flow — but that was down from $10.4B in 2024 due to higher capex and tax timing. The company retired $6.0B of debt in 2025, reducing leverage to 3.2x, but still carries $54.6B in total debt against $9.1B in cash. Capital allocation is prioritizing deleveraging and R&D investment ($7B in 2025, up 22%) over buybacks — there were zero share repurchases in 2025. The 2026 guidance of $37.0-$38.4B in revenue and $21.60-$23.00 non-GAAP EPS implies continued growth through the biosimilar headwinds on Prolia/XGEVA.

1-Year Performance

$351.02 current price. 52-week range of $261.43 to $391.29. The stock hit an all-time closing high of $388.16 on February 27, 2026, but has pulled back ~10% since.

Amgen's stock has been volatile around binary pipeline events and pricing policy news. The run from the $261 low (mid-2025, around the MariTide Phase 2 full data disappointment at ADA) to the $388 high (post-Q4 2025 earnings beat) was fueled by the VESALIUS-CV Repatha data, IMDELLTRA full approval, and strong portfolio execution. The recent pullback reflects uncertainty around biosimilar erosion timing for Prolia/XGEVA, Inflation Reduction Act impacts on Enbrel/Otezla pricing, and broader market risk-off sentiment. The stock's beta of 0.47 makes it a classic defensive play, and the ~2.9% dividend yield adds to its value appeal. Analyst consensus is split: median target of ~$355 with a range from $200 to $432, reflecting deep disagreement on MariTide's commercial potential and the severity of patent cliff headwinds.

Recent News

Fun Fact: Amgen's original name was Applied Molecular Genetics, Inc. — shortened to 'AMGen' — and its first product attempt was not a pharmaceutical at all. The company initially explored producing indigo dye using genetically engineered bacteria before pivoting to erythropoietin (EPO), the kidney hormone that stimulates red blood cell production. That pivot produced Epogen, which became the first blockbuster biotech drug and helped establish the entire biotechnology industry's commercial viability. Today, Amgen's deCODE genetics subsidiary in Iceland has sequenced more than half a million genomes from UK Biobank volunteers and maintains over 200 petabytes of de-identified human data — one of the largest proprietary human genetic datasets on Earth — all running on a supercomputer named 'Freyja' after the Norse goddess of life and prophecy.